Searched for
GLENMARK AND RANBAXY
Alkem Labs CEO Vikas Gupta may exit companyAlkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...- Rouble fallout: Dr Reddy's, Ranbaxy's profit in troubleDepreciation of the Russian currency poses a risk to the profitability of Indian pharma companies such as Dr Reddy's, Glenmark and Ranbaxy.
- Sun Pharma tops domestic drugmakers' list; Cipla and Ranbaxy slip two positions eachMumbai-based Sun Pharma has made it to the top of the domestic drug makers’ leaderboard through overseas acquisitions and quadrupling of re...
- Glenmark joins pharma companies setting up US plantsOver the years, leading companies like Ranbaxy, Sun Pharma and Dr Reddy's have either invested in greenfield facilities or acquired existin...
- IT, Pharma under pressure; Infosys, TCS, Sun Pharma take a hitStocks in IT and pharma sector took a beating for a 2nd consecutive session on Monday, weighed down by the rupee which hit its strongest in...
- Go for Glenmark Pharma than Ranbaxy or Wockhardt: Jagannadham ThunuguntlaIf somebody is very keen on pharma, we have a better perspective on Glenmark Pharma than Ranbaxy or Wockhardt, he said.
- Putting target number on Wockhardt difficult: Avinnash GorakssakarPutting a target number on Wockhardt would be difficult because already we have seen 30-40% upside.
- Pharma companies grapple with rise in other expensesThe other expenses of these companies rose at a much higher pace than their revenues over the last three years, says a study.
- Ranbaxy slips to 8th position in market-capitalisationRanbaxy has slipped to eighth position and the current m-cap of Rs 14,620 crore is below its average m-cap for 2006.
- Ranbaxy, Cipla and Glenmark may go up by 20-25% in longer term: K R Choksey SecuritiesRanbaxy, Cipla and Glenmark kind of companies would have a scope to go up by around 20% to 25% again in next 12 to 18 months time from now.
- Prefer midcap companies like Divis Laboratories, Glenmark, Cipla over Ranbaxy: Gaurang ShahAs a brokerage house we have a reduced recommendation on Ranbaxy and our target on the lower side : As low as 360 or 365.
- Bullish on Ranbaxy: Ashwani GujralFirstly trying to buy a stock after five days of rally is a sure way of getting trapped into a correction, so Ranbaxy probably needs to mov...
- Prefer Glenmark to Ranbaxy: Sandeep WagleI would definitely prefer Glenmark to Ranbaxy because Ranbaxy gave a breakdown three or four days back when it broke the Rs 450 level and c...
- Glenmark gets most approvals to sell generic drugs in USRanbaxy, now owned by Japan’s Daiichi Sankyo, may get nod to sell generic version of world’s best selling drug Lipitor worth over $12 billi...
- Glenmark may return 20-22% on target 370-380: Anagram CapitalRanbaxy and a Glenmark look quite positive.
- Buy Ranbaxy, Vijaya Bank & McDowell's: Sandeep Wagle, APTARTWe have a buy in Ranbaxy, Vijaya Bank and McDowell's and this leg of rally will be stock specific.
- Very bullish on Glenmark: Aunali Rupani, ARM ResearchNext 5 years will see a big run up in all the pharma stocks in India especially R&D.
- Teva, Glenmark call an end to patent disputeIsraeli generic major Teva and Mumbai-based Glenmark Pharmaceuticals have settled a patent dispute over various generic versions of Coreg -...
- Glenmark Pharma looks to out-license two molecules this yearGlenmark Pharmaceuticals on Friday said it would look at out-licensing two of its molecules this year that are in clinical trials.
- Glenmark gets US nod for pravastatin sodiumGlenmark Pharmaceuticals announced on Wednesday that it had received approval in the US to market a generic version of Bristol Myers Squibb...
Load More
